Notes
2014 British pounds
Reference
Graham J, et al. Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria. PharmacoEconomics : 12 May 2016. Available from: URL: http://doi.org/10.1007/s40273-016-0412-1
Rights and permissions
About this article
Cite this article
Omalizumab cost effective for chronic urticaria in UK. PharmacoEcon Outcomes News 754, 20 (2016). https://doi.org/10.1007/s40274-016-3090-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3090-5